Mercaptopurine (6-MP) for the Treatment of Manifestations of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)
Jonsson Comprehensive Cancer Center
Summary
This phase I/II trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is a rare inherited disorder that increases the risk of developing benign (not cancer) tumors of the skin and the uterus (leiomyomas) and malignant (cancer) tumors of the uterus (leiomyosarcoma) and the kidney. Mercaptopurine is in a class of medications called purine antagonists. It works by stopping the growth of cancer cells.
Description
PRIMARY OBJECTIVE: I. To identify the safety, side effects, and best dose of mercaptopurine (6-MP). SECONDARY OBJECTIVES: I. To assess clinical activity in treating metastatic fumarate hydratase (FH) Deficient Kidney Cancer. II. To assess how treatment impacts uterine fibroid clinical symptoms. III. To determine the change in menstrual bleeding. IV. To evaluate changes in pain due to leiomyomas. V. To evaluate the overall improvement in leiomyoma symptoms. EXPLORATORY OBJECTIVES: I. Associate changes in serum thiopurine metabolites (6-methylmercaptopurine \[6-MMP\] and 6-thioguanine \[6-…